10x Genomics Inc (NASDAQ:TXG) price on Thursday, February 27, fall -7.47% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $10.78.
A look at the stock’s price movement, the close in the last trading session was $11.65. Turning to its 52-week performance, $48.42 and $10.63 were the 52-week high and 52-week low respectively. Overall, TXG moved -27.36% over the past month.
10x Genomics Inc’s market cap currently stands at around $1.32 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 133.55M for the company’s revenue for the quarter, with a low and high estimate of 121.3M and 147.9M respectively. The average forecast suggests down to a -5.29% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 612.62M, representing a 0.30% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TXG is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
8 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 5 analyst(s) rate the stock as a Hold, 3 recommend TXG as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TXG’s current price about -15.16% and -23.24% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 30.84, while 7-day volatility ratio is 6.82% and 7.23% in the 30-day chart. Further, 10x Genomics Inc (TXG) has a beta value of 1.92, and an average true range (ATR) of 0.96. Analysts have given the company’s stock an average 52-week price target of $25, forecast between a low of $24 and high of $46. Looking at the price targets, the low is -122.63% off current price level while to achieve the yearly target high, price needs to move -326.72%. Nonetheless, investors will most likely welcome a -131.91% jump to $25 which is the analysts’ median price.
If we refocus on 10x Genomics Inc (NASDAQ:TXG), historical trading data shows that trading volumes averaged 2.24 million over the past 3 months. The company’s latest data on shares outstanding shows there are 108.24 million shares.
The 17.08% of 10x Genomics Inc’s shares are in the hands of company insiders while institutional holders own 79.45% of the company’s shares. Current price change has pushed the stock -24.93% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TXG stock continues to rise going into the next quarter.
